NASDAQ:ASLN - ASLAN PHARMACEU/ADR News Headlines

Sign in or create an account to add this stock to your watchlist.
$3.20 -0.02 (-0.62 %)
(As of 05/27/2019 06:00 AM ET)
Previous Close$3.20
Today's Range$3.20 - $3.49
52-Week Range$2.51 - $10.44
Volume175,281 shs
Average Volume12,049 shs
Market Capitalization$102.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

ASLAN PHARMACEU/ADR (NASDAQ ASLN) News Headlines

Source:
DateHeadline
 ASLAN PHARMACEU/ADR (ASLN) Given Average Recommendation of "Buy" by Analysts ASLAN PHARMACEU/ADR (ASLN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 14 at 7:24 AM
Zacks: Analysts Expect ASLAN PHARMACEU/ADR (ASLN) to Announce -$0.20 EPSZacks: Analysts Expect ASLAN PHARMACEU/ADR (ASLN) to Announce -$0.20 EPS
www.americanbankingnews.com - May 12 at 8:22 AM
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's WhyASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why
finance.yahoo.com - May 6 at 11:40 AM
ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - April 29 at 11:30 AM
Asian ADRs in Tuesday TradingAsian ADRs in Tuesday Trading
www.nasdaq.com - April 2 at 11:33 AM
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic DermatitisASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
finance.yahoo.com - March 29 at 12:29 PM
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate UpdateASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - March 22 at 12:09 PM
ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South KoreaASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea
finance.yahoo.com - March 11 at 8:55 AM
ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South KoreaASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
finance.yahoo.com - February 27 at 12:13 PM
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate RestructuringASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
finance.yahoo.com - January 30 at 11:31 AM
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug StudyThe Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
finance.yahoo.com - January 25 at 3:44 PM
Aslan Pharmaceuticals Ltd. ADRAslan Pharmaceuticals Ltd. ADR
www.barrons.com - January 24 at 3:44 PM
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell LinesASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
finance.yahoo.com - January 23 at 11:13 AM
ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GIASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
finance.yahoo.com - January 15 at 11:04 AM
[$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy[$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy
finance.yahoo.com - January 15 at 11:04 AM
ASLAN's Varlitinib Fails to Meet Endpoint in Phase II StudyASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
finance.yahoo.com - January 14 at 3:40 PM
ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric CancerASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer
finance.yahoo.com - January 13 at 6:22 PM
Asian ADRs Move Sharply Higher in Friday TradingAsian ADRs Move Sharply Higher in Friday Trading
www.nasdaq.com - January 4 at 3:34 PM
ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review PeriodASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
finance.yahoo.com - January 4 at 9:29 AM
ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of ScheduleASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
finance.yahoo.com - January 2 at 10:45 AM
New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid LeukaemiaNew Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia
finance.yahoo.com - December 2 at 3:27 PM
Asian ADRs Rebound in Tuesday TradingAsian ADRs Rebound in Tuesday Trading
www.nasdaq.com - November 27 at 3:25 PM
Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare ConferenceAslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 20 at 9:47 AM
ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 9:41 AM
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual MeetingASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 3:29 PM
ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent DirectorASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director
finance.yahoo.com - October 30 at 9:18 AM
New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC PatientsNew Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients
finance.yahoo.com - October 22 at 9:01 AM
ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic DermatitisASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
finance.yahoo.com - October 17 at 3:21 PM
ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology CongressASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress
finance.yahoo.com - October 9 at 8:52 AM
ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual MeetingASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting
finance.yahoo.com - October 3 at 8:34 AM
ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in ChinaASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China
finance.yahoo.com - September 17 at 8:12 AM
ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment ConferenceASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference
finance.yahoo.com - September 4 at 8:16 AM
ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid LeukaemiaASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia
finance.yahoo.com - August 20 at 6:23 AM
ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric CancerASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer
finance.yahoo.com - August 10 at 3:18 PM
ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 6 at 7:18 AM
ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004
finance.yahoo.com - July 3 at 8:16 AM
Analysts Roar Praise For Aslan, But Leerink More TepidAnalysts Roar Praise For Aslan, But Leerink More Tepid
finance.yahoo.com - May 31 at 5:01 AM
This page was last updated on 5/27/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel